Cargando…
17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2
INTRODUCTION: 17-allyamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is currently in clinical trials in breast cancer. However, 17-AAG treatment often results in inhibition of tumor growth rather than shrinkage, making detection of response a challenge. Magnetic resonan...
Autores principales: | Brandes, Alissa H, Ward, Christopher S, Ronen, Sabrina M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096977/ https://www.ncbi.nlm.nih.gov/pubmed/20946630 http://dx.doi.org/10.1186/bcr2729 |
Ejemplares similares
-
Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters
por: Pastvova, Nikola, et al.
Publicado: (2021) -
HDAC Inhibition Induces Increased Choline Uptake and Elevated Phosphocholine Levels in MCF7 Breast Cancer Cells
por: Ward, Christopher S., et al.
Publicado: (2013) -
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
por: Aregbe, Abdulateef O., et al.
Publicado: (2012) -
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells
por: Yao, Jia-Qi, et al.
Publicado: (2010) -
Radioprotective effects of oral 17-dimethylaminoethylamino-17-demethoxygeldanamycin in mice: bone marrow and small intestine
por: Lu, Xinyue, et al.
Publicado: (2013)